Great report! Stock is likely to re-rate to the upside
A
what is going on with this drop? There is no apparent news release. they are expected to post a decent quarter. i don't think this selloff is justified
A
The fundamentals of this company are exceptional. Margins are nothing special but it's holding its own. Should be back over 50 after ER in May.
W
Coming down to 23
A
Volume pretty much dead here and I'm the only one posting. Well I don't care if it stays rangebound until ER, with that order backlog, I know it's going higher. Average price target is $60+ I'll gladly take a 20% ROI. A little PR wouldn't hurt
A
What a phenomenal ER. The highlights:
Revenues increased 55.6% year over year to $522.1 million.
Earnings from operations were $55.4 million (10.6% operating margin), compared to $23.4 million (7.0% operating margin) a year ago. Adjusted earnings from operations1 were $70.7 million (13.5% margin), compared to $40.1 million (12.0% margin) a year ago.
EBITDA1 was $81.2 million (15.6% EBITDA margin), compared to $41.5 million (12.4% EBITDA margin) a year ago. Adjusted EBITDA1 was $83.3 million (16.0% adjusted EBITDA margin), compared to $49.6 million (14.8% adjusted EBITDA margin) a year ago.
Earnings per share were 41 cents basic and diluted compared to 13 cents a year ago.
Adjusted basic earnings per share were 53 cents compared to 26 cents a year ago.
Order Bookings were $510 million, 26.6% higher compared to $403 million a year ago.
Order Backlog increased 35.5% to $1,295 million at September 26, 2021 compared to $956 million a year ago.
A
Talk about a strategic acquisition... bridges to further pharmaceutical development and higher margin revenue streams.
CAMBRIDGE, ON, Nov. 7, 2021 /CNW/ - ATS Automation Tooling Systems Inc. (TSX: ATA) ("ATS" or the "Company"), an industry-leading automation solutions provider, today announced it has entered into a definitive agreement to acquire SP Industries, Inc. ("SP"), a designer and manufacturer of high-grade biopharma processing equipment, life sciences equipment, and lab apparatus products for US$445 million (~C$550 million), subject to customary post-closing adjustments, representing 15.3x SP's trailing 12 month adjusted EBITDA or 11.9x post synergies.
"SP greatly expands our capabilities and offerings through the addition of its aseptic and non-aseptic lyophilization portfolio and its fill-finish solutions and enhances our position in the pharmaceutical drug development and production end-markets," said Andrew Hider, CEO of ATS. "SP participates in highly attractive segments where growth is driven by a robust pharma drug pipeline, rising usage of biologics and increasing lyophilization of products. Notably, the combination of ATS and SP will allow us to better support the needs of our customers throughout the lifecycle of pharmaceutical development and production, as well as in diagnostics, broader life sciences and applied sciences applications. With its proven track record and talented team, SP will be a strong contributor to the ATS family offering compelling sales synergy potential with our life sciences businesses including Comecer."
is the tesla acquisition a good thing for the stock
E
Why is this stock always green?
S
Wow glad I bought this at 29 dollars. Sadly only 100 shares
A
Volume still meh but someone bought 40,500 shares at 12:23pm around 42.70, that's confidence..
A
Just acquired a company yesterday. Company is doing great. Not sure why the big drop.
E
Amazing earnings! To $50 we go!
M
ATS Acquires Intellectual Property Assets of VASPAC Tue, February 22, 2022, 8:00 a.m.
About VASPAC VASPAC was founded in 2003 to provide process control solutions for the Nuclear Power Generation market, specializing in nuclear safety-related software. Leveraging an extensive power generation and formal software development background, VASPAC has developed nuclear-grade solutions which are considered the gold standard amongst clients. For more information, visit VASPAC's website www.vaspac.ca.
VASPAC Inc
www.vaspac.ca.
P
ATA.TO is up more than 75% since October 2020 but this board is so quiet.
A
Nothing major but a solid acquisition. I don't lose any sleep over this one.
F
Ouch!
A
ER is Feb 2 at 8:30am. Another top choice from Justin Heywood (Stifel). Most price targets are showing 25% upside. Margins are growing, huge revenue backlog. Generating 3 times as much revenue per share as CTS which I also adore
Revenues increased 55.6% year over year to $522.1 million.
Earnings from operations were $55.4 million (10.6% operating margin), compared to $23.4 million (7.0% operating margin) a year ago. Adjusted earnings from operations1 were $70.7 million (13.5% margin), compared to $40.1 million (12.0% margin) a year ago.
EBITDA1 was $81.2 million (15.6% EBITDA margin), compared to $41.5 million (12.4% EBITDA margin) a year ago. Adjusted EBITDA1 was $83.3 million (16.0% adjusted EBITDA margin), compared to $49.6 million (14.8% adjusted EBITDA margin) a year ago.
Earnings per share were 41 cents basic and diluted compared to 13 cents a year ago.
Adjusted basic earnings per share were 53 cents compared to 26 cents a year ago.
Order Bookings were $510 million, 26.6% higher compared to $403 million a year ago.
Order Backlog increased 35.5% to $1,295 million at September 26, 2021 compared to $956 million a year ago.
CAMBRIDGE, ON, Nov. 7, 2021 /CNW/ - ATS Automation Tooling Systems Inc. (TSX: ATA) ("ATS" or the "Company"), an industry-leading automation solutions provider, today announced it has entered into a definitive agreement to acquire SP Industries, Inc. ("SP"), a designer and manufacturer of high-grade biopharma processing equipment, life sciences equipment, and lab apparatus products for US$445 million (~C$550 million), subject to customary post-closing adjustments, representing 15.3x SP's trailing 12 month adjusted EBITDA or 11.9x post synergies.
"SP greatly expands our capabilities and offerings through the addition of its aseptic and non-aseptic lyophilization portfolio and its fill-finish solutions and enhances our position in the pharmaceutical drug development and production end-markets," said Andrew Hider, CEO of ATS. "SP participates in highly attractive segments where growth is driven by a robust pharma drug pipeline, rising usage of biologics and increasing lyophilization of products. Notably, the combination of ATS and SP will allow us to better support the needs of our customers throughout the lifecycle of pharmaceutical development and production, as well as in diagnostics, broader life sciences and applied sciences applications. With its proven track record and talented team, SP will be a strong contributor to the ATS family offering compelling sales synergy potential with our life sciences businesses including Comecer."
https://finance.yahoo.com/news/ats-reports-third-quarter-fiscal-110000087.html
Tue, February 22, 2022, 8:00 a.m.
About VASPAC
VASPAC was founded in 2003 to provide process control solutions for the Nuclear Power Generation market, specializing in nuclear safety-related software. Leveraging an extensive power generation and formal software development background, VASPAC has developed nuclear-grade solutions which are considered the gold standard amongst clients. For more information, visit VASPAC's website www.vaspac.ca.